Upper tract urothelial carcinomas (UTUC) of the renal pelvis or ureter can be difficult to 40 detect and challenging to diagnose. Here, we report the development and application of 41 a non-invasive test for UTUC based on molecular analyses of DNA recovered from cells 42 shed into the urine. The test, called UroSEEK, incorporates assays for mutations in eleven 43 genes frequently mutated in urologic malignancies and for allelic imbalances on 39 44 nitrophenanthrene carboxylic acid produced by Aristolochia plants (Hsieh et al., 2008; 61 
improve post-surgical management, particularly as urine cytology cannot detect the 84 majority of UTUCs (Baard et al., 2017) . 85 86 As UTUCs are in direct contact with the urine, we hypothesized that genetic analyses of 87 exfoliated urinary cells could be used to detect upper urinary tract neoplasm in a 88 noninvasive fashion (Figure 1 ). In the current study, we tested this hypothesis through 89 the analysis of urinary cell DNA using assays that could identify a variety of genetic 90 abnormalities. 91 92 93 102 moderate renal disease (CKD stage 3) or severe disease (CKD stages 4-5) was noted 103 for 43% and 12% of the cohort, respectively (Table 1) . There were 22 cases in which aneuploidy was observed in the urinary cell samples.
206
Overall, 96% of the chromosome gains or losses observed in the urinary cells were also 207 observed in the primary tumors (examples in Figure 4 ). Conversely there were 34 cases 208 in which aneuploidy was not observed in the urinary cell samples. Evaluation of the 56 209 tumors with the same assay showed that all but three were aneuploid, so as with 210 mutations, the main reason for failure of the aneuploidy assay was insufficient amounts 211 of neoplastic DNA in the urinary cells.
212 213 Biomarkers in combination. There are two factors that limit sensitivity for genetically214 based biomarkers. First, a sample can only be scored as positive for the biomarker if it 215 contains DNA from a sufficient number of neoplastic cells to be detected by the assay.
216
Second, the tumor from which the neoplastic cells were derived must harbor the genetic alteration that is queried. Combination assays can increase sensitivity by assessing more 216 genetic alterations, and are thereby more likely to detect at least one genetic alteration 217 present in the tumor. However, mutations in clinical samples often are present at low 218 allele frequencies (Supplementary Files 2 and 3), requiring high coverage of every base 219 queried. It would be prohibitively expensive to perform whole exome sequencing at 220 10,000x coverage, for example, so some compromise is needed. In our study, we To determine whether these theoretical arguments made a difference in practice, we 238 evaluated biomarker performance with the combined approaches, collectively called UroSEEK. As noted above, the ten-gene multiplex assay, the TERT singleplex assay, 240 and the aneuploidy assays yielded 64, 29%, and 39% sensitivities, respectively, when 241 used separately (Table 1) . Twenty-three samples without TERT promoter mutations 242 tested positive for mutations in one of the other ten genes (Venn diagram in Figure 2 ).
243
Conversely, three samples without detectable mutations with the multiplex assay scored UroSEEK test (specificity 99.5%, CI 97.5 to 100%).
251
To determine the basis for the increased sensitivity afforded by the combination assays, 252 we evaluated data from the primary tumors of the three patients whose urinary cell 253 samples exhibited aneuploidy but did not harbor detectable mutations. We found that 254 these three tumors did not contain any mutations in the 11 queried genes, explaining why 255 these same assays were negative when applied to urinary cell DNA. As noted above, 256 these three tumors were aneuploid, thus affording the opportunity to detect these copy 257 number variations in the urinary cell samples. suited for screening and the latter confers significant radiation exposure. Ureteroscopy 296 is often definitive, but in addition to being invasive, requires highly skilled clinicians and is 297 also ill-suited as a screening tool (Golan et al., 2015) . 309 Wang, Springer, Zhang, et al., 2015; Wang et al., 2016) . We chose the latter option for 310 the current study to increase the sensitivity and specificity of our biomarker assay. were identified in the matched urinary cell DNA samples. The superior performance in 320 urinary cells was likely due to a substantial enrichment for mutated DNA in these cells 321 compared to plasma: the median MAF in plasma when a mutation was detectable was 322 only 0.3% compared to 15% in the urinary cells.
324
Although the approach described here has significant potential for screening purposes, 325 we emphasize that the current study demonstrates proof-of-principle rather than clinical 326 applicability. Accordingly, there are several caveats to the study that are worthy of 327 attention. First, we only evaluated 56 patients. Second, the study was in essence 328 retrospective rather than prospective. Another "caveat" is that our assays on urinary cells 329 cannot distinguish between UTUC and bladder tumors, and the UroSEEK test could in 330 theory also detect kidney cancer. We consider this a strength rather than a weakness, because the detection of bladder or kidney cancer is as important as the detection of 332 UTUC. Bladder cancers are more common than UTUC in the general population (Roupret   333   et al., 2015) , and patients exposed to AA are at risk for bladder cancer and renal cell 334 carcinoma as well as for UTUC (Hoang et al., 2016; Lai et al., 2010) . KRAS, MET, MLL, PIK3CA, TP53, and VHL (Cancer Genome Atlas Research, 2014; 387 Lin et al., 2010; Mo et al., 2007; Netto, 2011; Sarkis et al., 1995; Sarkis et al., 1994; Sarkis 388 et al., 1993; Wu, 2005) . The 57 primer pairs used for this multiplex PCR were divided in 389 a total of three multiplex reactions, each containing non-overlapping amplicons 390 (Supplementary File 6) These primers were used to amplify DNA in 25 uL reactions as 391 previously described (Kinde et al., 2011) except that 15 cycles were used for the initial 392 amplification. Second, the TERT promoter region was evaluated. A single amplification 393 primer pair was used to amplify a 73-bp segment containing the region of the TERT 394 promoter known to harbor mutations in BC (Kinde, Munari, et al., 2013) . The conditions 395 used to amplify it were the same as used in the multiplex reactions described above Sidransky, D., Von Eschenbach, A., Tsai, Y. C., Jones, P., Summerhayes, I., Marshall,
